HRS-7058 + SHR-1826 + SHR-1316

HRS-7058 + SHR-1826 + SHR-1316 is an investigational combination therapy under clinical development for the treatment of advanced solid tumors. HRS-7058 is a novel, selective small molecule inhibitor targeting KRAS G12C mutations, designed to inhibit tumor growth in cancers harboring this mutation[2][7]. SHR-1826 is an antibody-drug conjugate (ADC) targeting c-Met, developed for use in combination with other antitumor therapies in advanced solid tumors and non-small cell lung cancer[3][5][7]. SHR-1316 is a monoclonal antibody that targets programmed death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses; it has shown efficacy when combined with chemotherapy in esophageal squamous cell carcinoma[4]. The combination aims to leverage targeted inhibition of oncogenic signaling (KRAS G12C), direct cytotoxicity via ADC against c-Met-expressing cells, and immune checkpoint blockade through PD-L1 inhibition.